Neoprobe announces early RIGScan data
This article was originally published in Clinica
Neoprobe's radiolabelled-immunodiagnostic RIGScan CR49 led to major changes to therapy in over 40% of colorectal cancer patients. Dr Schlomo Schneebaum, Neoprobe's European medical director and a clinical investigator at the Sourasky Medical Center in Tel Aviv, presented the data from an early cohort of the Phase III trial at the ECCO-8 cancer conference in Paris (October 29th-November 2nd).
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.